Roivant Sciences Ltd.
ROIV
株式のランク
#979
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
株価
$33.73
最終同期: 2026-07-31
時価総額
$24.37B
変化（1日）
-2.28%
変化（1年）
90.15%
国
GB
取引 Roivant Sciences Ltd. (ROIV)
カテゴリー
Healthcare
Roivant Sciences Ltd.（ROIV）の利益
Jun 2026 時点の利益 TTM: $-289.88M
Roivant Sciences Ltd. の最新の財務報告によると、同社の現在の利益は $-289.88M です。2024 年には $4.57B の利益を上げ、これは 2023 年の利益 $-1.22B と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Roivant Sciences Ltd. の利益の推移（2020 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $-289.88M | -57.47% |
| 2025 | $-681.59M | -114.92% |
| 2024 | $4.57B | -472.94% |
| 2023 | $-1.22B | 32.59% |
| 2022 | $-923.75M | 2.80% |
| 2021 | $-898.55M | 60.17% |
| 2020 | $-560.99M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | -1,919.68% |
US
|
|
| $-3.09B | 964.92% |
US
|
|
| $-4.02B | 1,285.47% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -772.92% |
NL
|
